8-K: Enliven Therapeutics Appoints New CEO, Rick Fair

Enliven Therapeutics announced the appointment of Rick Fair as its new President and CEO, effective December 11, 2025, with co-founder Samuel Kintz transitioning to Head of Pipeline.

Summary

• Richard Fair has been appointed President and Chief Executive Officer, and a member of the Board of Directors, effective December 11, 2025.
• Samuel Kintz, co-founder and former President and CEO, will assume a new role as Head of Pipeline, effective December 11, 2025.
• Mr. Fair brings over 25 years of experience in product development and commercialization, including 20 years with large pharmaceutical companies such as Roche/Genentech and Johnson & Johnson.
• Mr. Fair's compensation package includes an annual base salary of $660,000, an annual target bonus of 55% of his base salary, and a stock option to purchase 875,000 shares of common stock.
• Mr. Kintz's new role includes an annual base compensation of $500,000, eligibility for a 55% target bonus for 2025, and the acceleration and vesting of 140,457 shares subject to his outstanding stock options.
• The Board adopted the Enliven Therapeutics, Inc. 2025 Inducement Equity Incentive Plan, reserving 875,000 shares of common stock for issuance, primarily to attract new employees as an inducement, without stockholder approval pursuant to Nasdaq Listing Rules.

Sentiment

Score: 8

Explanation: The filing announces a strategic leadership transition aimed at strengthening the company for its next phase of growth, particularly late-stage clinical development and commercialization. The new CEO brings highly relevant experience, and the former CEO remains in a key role. This is a positive, forward-looking move for the company.

Positives

• The appointment of Rick Fair as CEO brings extensive experience in late-stage oncology and hematology product development and commercialization, including overseeing the launch of five new therapies and managing a $23 billion business at Roche/Genentech.
• Samuel Kintz, co-founder and former CEO, remains with the company as Head of Pipeline, retaining his expertise for early-stage research programs and expressing passion for discovery through proof-of-concept stage drug development.
• The leadership transition is strategically aimed at driving the next phase of development, including a pivotal Phase 3 trial for ELVN-001 and its commercialization.
• There will be a dedicated focus on developing and potentially advancing existing early pipeline assets to the clinic.
• ELVN-001 is believed to have the potential to be a best-in-class ATP-competitive inhibitor for CML, offering better efficacy, tolerability, and convenience than currently approved therapies.

Risks

• Limited operating history of Enliven.
• Ability to advance product candidates through clinical development.
• Ability to obtain regulatory approval for, and ultimately commercialize or license, product candidates.
• Outcome of preclinical testing and early clinical trials for product candidates may not be predictive of the success of later clinical trials.
• Enliven's limited resources.
• Risk of failing to demonstrate safety and efficacy of product candidates.
• Enliven's limited experience as a company in designing and conducting clinical trials.
• Potential for interim, topline, and preliminary data from preclinical studies and clinical trials to materially change from the final data.
• Potential delays or difficulties in the enrollment or maintenance of patients in clinical trials.
• Developments relating to Enliven's competitors and its industry, including competing product candidates and therapies.
• The decision to develop or seek strategic collaborations to develop current or future product candidates in combination with other therapies and the cost of combination therapies.
• Ability to attract, hire, and retain highly skilled executive officers and employees.
• Changes in any individual's plans in the future.
• Ability of Enliven to protect its intellectual property and proprietary technologies.
• The scope of any patent protection Enliven obtains or the loss of any of Enliven's patent protection.
• Reliance on third parties, including medical institutions, contract manufacturing organizations, contract research organizations and strategic partners.
• Geo-political developments, general market or macroeconomic conditions.
• Enliven's ability to obtain additional capital to fund general corporate activities and to fund research and development.

Future Outlook

The company plans to initiate a pivotal Phase 3 clinical trial for ELVN-001 in patients with chronic myeloid leukemia (CML) in 2026 and aims for its commercialization. There is also a dedicated focus to develop and potentially advance existing early pipeline assets to the clinic. Management believes ELVN-001 has the potential to be a best-in-class ATP-competitive inhibitor for CML, offering better efficacy, tolerability, and convenience.

Management Comments

• "I am pleased to announce the appointment of Rick Fair as Enlivens new CEO. Rick has substantial experience bringing late-stage oncology and hematology assets to commercialization. He joins us at a critical time as we plan to initiate a pivotal Phase 3 clinical trial of ELVN-001 in 2026. His expertise adds to Enlivens ability to design and execute a successful Phase 3 trial and commercialize ELVN-001 to deliver long-term value to our stockholders." Richard Heyman, Ph.D., Chairman of the Board of Directors.
• "I am very excited to join Enliven as CEO at this important phase and look forward to working with this team to bring ELVN-001 through its Phase 3 trial and to market. The data generated to date demonstrate that ELVN-001 has the potential to be the best-in-class ATP-competitive inhibitor for the treatment of CML and provide patients with CML a treatment with better efficacy, tolerability and convenience than currently approved therapies." Rick Fair, new President and CEO.
• "We are extremely grateful to Sam for his significant contributions to Enliven and look forward to his continued work leading our early-stage research programs. As a co-founder and CEO of Enliven, Sam has been instrumental in the early development of ELVN-001 and advancing the program into clinical trials. The Board is excited that Sam will remain engaged with Enliven to lead our existing early pipeline initiatives. Thanks to Sam and the team, we remain well positioned clinically and financially to execute on our next phase of growth." Richard Heyman, Ph.D., Chairman of the Board of Directors.
• "We welcome Rick and his deep product development and commercialization experience during this incredibly exciting time. I am proud of the teams achievements to date and remain committed to the long-term success of Enliven and ELVN-001. I am also excited to return to my roots to lead our early pipeline efforts. I started my career as a medicinal chemist, and I am most passionate about the discovery through proof-of-concept stage of drug development. We have ongoing efforts that I believe could further transform Enliven and provide long-term value to our stockholders. I truly believe these leadership changes are best for Enlivens future. It has been a pleasure serving as Enlivens CEO, and I am confident that Rick is the right person to lead us through our next chapter." Samuel Kintz, Co-Founder and former CEO.

Industry Context

The biopharmaceutical industry, particularly in oncology and hematology, is highly competitive and requires significant expertise in clinical development and commercialization. Enliven's move to bring in a CEO with deep commercialization experience for late-stage assets, while retaining the co-founder for early pipeline development, reflects a strategic shift towards later-stage clinical trials and market entry, common for companies transitioning from early-stage research to commercialization. The focus on "best-in-class" therapies for CML indicates a competitive landscape where differentiation is key.

Comparison to Industry Standards

• The appointment of a seasoned executive with over 25 years of experience, including leadership roles at major pharmaceutical companies like Roche/Genentech and Johnson & Johnson, aligns with industry best practices for companies transitioning to late-stage clinical development and commercialization. This mirrors transitions seen at companies like Mirati Therapeutics (now part of BMS) or Seagen (now part of Pfizer) as they moved from clinical-stage to commercial-stage, often bringing in executives with strong commercial backgrounds.
• Retaining the co-founder in a dedicated Head of Pipeline role is a common strategy to leverage founding expertise in early-stage innovation while bringing in new leadership for commercial execution. This reflects structures seen in companies like Moderna or BioNTech, where scientific founders often maintain key R&D roles while commercial leadership is brought in.
• The compensation package for the new CEO, including a substantial base salary ($660,000), significant target bonus (55%), and a large equity grant (875,000 shares), is competitive for a CEO of a clinical-stage biopharmaceutical company, especially one preparing for a pivotal Phase 3 trial. This is comparable to executive compensation at similar-sized biotech firms like Relay Therapeutics or Revolution Medicines at similar stages of development.
• The adoption of an Inducement Equity Incentive Plan under Nasdaq Listing Rules is a standard mechanism for attracting high-caliber external talent in the biotech sector, allowing for significant equity grants without requiring immediate shareholder approval for individual awards.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for long-term value creation through strengthened leadership for late-stage development and commercialization of ELVN-001, and continued focus on pipeline innovation.
• Employees: New CEO brings extensive experience, potentially offering new strategic direction and opportunities. Samuel Kintz's new role provides continuity and focus on early-stage programs.
• Customers (future patients): Enhanced focus on bringing ELVN-001 to market and developing new therapies aims to address unmet medical needs.
• Management: Clear roles defined for the new CEO and the former CEO, aligning expertise with strategic priorities.

Next Steps

• Initiate a pivotal Phase 3 clinical trial for ELVN-001 in patients with chronic myeloid leukemia (CML) in 2026.
• Commercialize ELVN-001.
• Develop and potentially advance existing early pipeline assets to the clinic.
• Samuel Kintz to enter into agreements with the Company regarding his new compensation and benefits.

Key Dates

Recommendation

The appointment of Rick Fair, a highly experienced executive in late-stage oncology/hematology product development and commercialization, is a significant positive for Enliven Therapeutics as it prepares for a pivotal Phase 3 trial for ELVN-001 and its eventual market launch. Retaining co-founder Samuel Kintz in a dedicated Head of Pipeline role ensures continuity and focus on early-stage innovation. This strategic leadership restructuring positions the company strongly for its next phase of growth, enhancing its ability to execute on clinical and commercial objectives, which should drive long-term shareholder value. The clear strategic alignment and strong executive team suggest a positive outlook for the company's future performance.

Keywords

Enliven Therapeutics, ELVN, CEO appointment, Rick Fair, Samuel Kintz, Head of Pipeline, biopharmaceutical, clinical-stage, oncology, hematology, CML, ELVN-001, Phase 3 trial, commercialization, equity incentive plan, corporate governance, executive compensation